Co-Diagnostics, Inc.

Equities

CODX

US1897631057

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:03:20 2024-04-24 am EDT 5-day change 1st Jan Change
1.145 USD -0.43% Intraday chart for Co-Diagnostics, Inc. -0.88% -15.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event CI
Co-Diagnostics, Inc. Appoints Executive Appointments CI
Co-Diagnostics, Inc. Appoints Richard Abbott as President CI
Transcript : Co-Diagnostics, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022. CI
Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Co-Diagnostics Gets Approval From India's Central Drugs Standard Control Organization For Manufacturing, Sale of Influenza Multiplex Test MT
Co-Diagnostics Submits PCR COVID-19 Test and PCR Pro Instrument for FDA Review MT
Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform DJ
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $3 From $2, Maintains Neutral Rating MT
Transcript : Co-Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $2.5M MT
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022. CI
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from S&P Global BMI Index CI
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $3, Keeps Neutral Rating MT
Transcript : Co-Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022. CI
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q2 Revenue $0.2M MT
Co-Diagnostics Wins Gates Foundation Grants for Tuberculosis, HPV Tests MT
Co-Diagnostics, Inc. Announces Recent Grant Awards CI
Co-Diagnostics Receives $1.2 Million in New Funds From National Institutes of Health MT
Chart Co-Diagnostics, Inc.
More charts
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.15 USD
Average target price
2.5 USD
Spread / Average Target
+117.39%
Consensus
  1. Stock Market
  2. Equities
  3. CODX Stock
  4. News Co-Diagnostics, Inc.
  5. Co-Diagnostics Says Its COVID-19 Tests Not Affected by Omicron Variant